PCV
Vaccines below this line are for selected populations
Range of recommended ages Catch-up vaccination Preadolescent assessment
1. Hepatitis B vaccine (Hep B). All infants should receive the first dose of hepatitis
B vaccine soon after birth and before hospital discharge; the first dose may
also be given by age 2 months if the infant?s mother is HBsAg-negative. Only
monovalent hepatitis B vaccine can be used for the birth dose. Monovalent or
combination vaccine containing Hep B may be used to complete the series; four
doses of vaccine may be administered if combination vaccine is used. The second
dose should be given at least 4 weeks after the first dose, except for Hib-containing
vaccine which cannot be administered before age 6 weeks. The third
dose should be given at least 16 weeks after the first dose and at least 8 weeks
after the second dose. The last dose in the vaccination series (third or fourth
dose) should not be administered before age 6 months.
Infants born to HBsAg-positive mothers should receive hepatitis B vaccine and
0.5 mL hepatitis B immune globulin (HBIG) within 12 hours of birth at separate
sites. The second dose is recommended at age 1-2 months and the vaccination
series should be completed (third or fourth dose) at age 6 months.
Infants born to mothers whose HBsAg status is unknown should receive the
first dose of the hepatitis B vaccine series within 12 hours of birth. Maternal
blood should be drawn at the time of delivery to determine the mother?s HBsAg
status; if the HBsAg test is positive, the infant should receive HBIG as soon as possible
(no later than age 1 week).
2. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).
The fourth dose of DTaP may be administered as early as age 12 months, provided
6 months have elapsed since the third dose and the child is unlikely to
return at age 15-18 months. Tetanus and diphtheria toxoids (Td) is recommended
at age 11-12 years if at least 5 years have elapsed since the last dose of
tetanus and diphtheria toxoid-containing vaccine. Subsequent routine Td boosters
are recommended every 10 years.
3. Haemophilus influenzae type b (Hib) conjugate vaccine. Three Hib conjugate
vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB? or
ComVax? [Merck]) is administered at ages 2 and 4 months, a dose at age 6
months is not required. DTaP/Hib combination products should not be used for
primary immunization in infants at ages 2, 4 or 6 months, but can be used as
boosters following any Hib vaccine.
4. Inactivated polio vaccine (IPV). An all-IPV schedule is recommended for routine
childhood polio vaccination in the United States. All children should receive
four doses of IPV at ages 2 months, 4 months, 6-18 months, and 4-6 years.
5. Measles, mumps, and rubella vaccine (MMR). The second dose of MMR is
recommended routinely at age 4-6 years but may be administered during any
visit, provided at least 4 weeks have elapsed since the first dose and that both
doses are administered beginning at or after age 12 months. Those who have
not previously received the second dose should complete the schedule by the
11-12 year old visit.
6. Varicella vaccine. Varicella vaccine is recommended at any visit at or after age
12 months for susceptible children, i.e. those who lack a reliable history of chickenpox.
Susceptible persons aged >13 years should receive two doses, given at
least 4 weeks apart.
7. Pneumococcal vaccine. The heptavalent pneumococcal conjugate vaccine
(PCV) is recommended for all children age 2-23 months. It is also recommended
for certain children age 24-59 months. Pneumococcal polysaccharide vaccine
(PPV) is recommended in addition to PCV for certain high-risk groups. See
MMWR. 2000;49(RR-9):1-35.
8. Hepatitis A vaccine. Hepatitis A vaccine is recommended for use in selected
states and regions, and for certain high-risk groups; consult your local public
health authority. See MMWR. 1999;48(RR-12):1-37.
9. Influenza vaccine. Influenza vaccine is recommended annually for children
age > 6 months with certain risk factors (including but not limited to asthma,
cardiac disease, sickle cell disease, HIV, diabetes; see MMWR. 2001;50(RR-4):1-
44), and can be administered to all others wishing to obtain immunity. Children
aged =12 years should receive vaccine in a dosage appropriate for their age (0.25
mL if age 6-35 months or 0.5 mL if age =3 years). Children aged =8 years who are
receiving influenza vaccine for the first time should receive two doses separated
by at least 4 weeks.
For additional information about vaccines, vaccine supply, and contraindications
for immunization, please visit the National Immunization Program Web site at
www.cdc.gov/nip or call the National Immunization Hotline at (800) 232-2522
(English) or (800) 232-0233 (Spanish).
|